Cargando…

Macrophage Activation Markers Predict Liver-Related Complications in Primary Biliary Cholangitis

Primary biliary cholangitis (PBC) has a wide variation in clinical presentation and course. There is no significant correlation between these symptoms and the disease stage, although patients with more advanced stages generally have more symptoms. It is important to develop biomarkers in order to id...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujinaga, Yukihisa, Namisaki, Tadashi, Tsuji, Yuki, Suzuki, Junya, Murata, Koji, Takeda, Soichi, Takaya, Hiroaki, Inoue, Takashi, Noguchi, Ryuichi, Fujimoto, Yuki, Enomoto, Masahide, Nishimura, Norihisa, Kitagawa, Koh, Kaji, Kosuke, Kawaratani, Hideto, Akahane, Takemi, Mitoro, Akira, Yoshiji, Hitoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456095/
https://www.ncbi.nlm.nih.gov/pubmed/36077228
http://dx.doi.org/10.3390/ijms23179814
_version_ 1784785727665471488
author Fujinaga, Yukihisa
Namisaki, Tadashi
Tsuji, Yuki
Suzuki, Junya
Murata, Koji
Takeda, Soichi
Takaya, Hiroaki
Inoue, Takashi
Noguchi, Ryuichi
Fujimoto, Yuki
Enomoto, Masahide
Nishimura, Norihisa
Kitagawa, Koh
Kaji, Kosuke
Kawaratani, Hideto
Akahane, Takemi
Mitoro, Akira
Yoshiji, Hitoshi
author_facet Fujinaga, Yukihisa
Namisaki, Tadashi
Tsuji, Yuki
Suzuki, Junya
Murata, Koji
Takeda, Soichi
Takaya, Hiroaki
Inoue, Takashi
Noguchi, Ryuichi
Fujimoto, Yuki
Enomoto, Masahide
Nishimura, Norihisa
Kitagawa, Koh
Kaji, Kosuke
Kawaratani, Hideto
Akahane, Takemi
Mitoro, Akira
Yoshiji, Hitoshi
author_sort Fujinaga, Yukihisa
collection PubMed
description Primary biliary cholangitis (PBC) has a wide variation in clinical presentation and course. There is no significant correlation between these symptoms and the disease stage, although patients with more advanced stages generally have more symptoms. It is important to develop biomarkers in order to identify patients with an increased risk of complications and end-stage liver disease. This study investigated surrogate markers for risk estimation of PBC-related complications, including a study population of 77 patients with PBC who underwent liver biopsy and were measured for serum levels of macrophage activation markers, soluble CD163 (sCD163), soluble mannose receptor (sMR), and zonulin. Patients with PBC were divided into symptomatic (Group S, n = 20) and asymptomatic (Group A, n = 57) groups. The correlations of histological stages based on both Scheuer and Nakanuma classifications with the three serum markers were investigated. The Nakanuma classification involves grading for liver fibrosis and bile duct loss. The three biomarkers were assessed for their diagnostic ability to identify patients with PBC having high risk of developing complications. The predictive factors of these complications were examined as well. Group S had significantly higher serum sMR (p = 0.011) and sCD163 (p = 0.048) levels versus Group A. A composite index of sMR and sCD163 measurements had significantly better prediction performance than sCD163 alone (p = 0.012), although not when compared to sMR alone (p = 0.129). Serum sMR was an independent factor for developing complications on both univariate (Odds ratio (OR) = 30.20, 95% confidence interval (95% CI): 3.410–267.0, p = 0.00220), and multivariate (OR = 33.70, 95% CI: 3.6600–311.0, p = 0.0019) analyses. Patients with PBC having sMR of ≥56.6 had a higher incidence of clinical complications versus those with a sMR of <56.6. Serum sMR predicts the development of complications in patients with PBC. sMR plus sCD163 showed better predictive power than either marker alone, although the addition of sCD163 did not improve the predictive power of sMR. Future prospective studies are required in order to validate the findings of the present study.
format Online
Article
Text
id pubmed-9456095
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94560952022-09-09 Macrophage Activation Markers Predict Liver-Related Complications in Primary Biliary Cholangitis Fujinaga, Yukihisa Namisaki, Tadashi Tsuji, Yuki Suzuki, Junya Murata, Koji Takeda, Soichi Takaya, Hiroaki Inoue, Takashi Noguchi, Ryuichi Fujimoto, Yuki Enomoto, Masahide Nishimura, Norihisa Kitagawa, Koh Kaji, Kosuke Kawaratani, Hideto Akahane, Takemi Mitoro, Akira Yoshiji, Hitoshi Int J Mol Sci Article Primary biliary cholangitis (PBC) has a wide variation in clinical presentation and course. There is no significant correlation between these symptoms and the disease stage, although patients with more advanced stages generally have more symptoms. It is important to develop biomarkers in order to identify patients with an increased risk of complications and end-stage liver disease. This study investigated surrogate markers for risk estimation of PBC-related complications, including a study population of 77 patients with PBC who underwent liver biopsy and were measured for serum levels of macrophage activation markers, soluble CD163 (sCD163), soluble mannose receptor (sMR), and zonulin. Patients with PBC were divided into symptomatic (Group S, n = 20) and asymptomatic (Group A, n = 57) groups. The correlations of histological stages based on both Scheuer and Nakanuma classifications with the three serum markers were investigated. The Nakanuma classification involves grading for liver fibrosis and bile duct loss. The three biomarkers were assessed for their diagnostic ability to identify patients with PBC having high risk of developing complications. The predictive factors of these complications were examined as well. Group S had significantly higher serum sMR (p = 0.011) and sCD163 (p = 0.048) levels versus Group A. A composite index of sMR and sCD163 measurements had significantly better prediction performance than sCD163 alone (p = 0.012), although not when compared to sMR alone (p = 0.129). Serum sMR was an independent factor for developing complications on both univariate (Odds ratio (OR) = 30.20, 95% confidence interval (95% CI): 3.410–267.0, p = 0.00220), and multivariate (OR = 33.70, 95% CI: 3.6600–311.0, p = 0.0019) analyses. Patients with PBC having sMR of ≥56.6 had a higher incidence of clinical complications versus those with a sMR of <56.6. Serum sMR predicts the development of complications in patients with PBC. sMR plus sCD163 showed better predictive power than either marker alone, although the addition of sCD163 did not improve the predictive power of sMR. Future prospective studies are required in order to validate the findings of the present study. MDPI 2022-08-29 /pmc/articles/PMC9456095/ /pubmed/36077228 http://dx.doi.org/10.3390/ijms23179814 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Fujinaga, Yukihisa
Namisaki, Tadashi
Tsuji, Yuki
Suzuki, Junya
Murata, Koji
Takeda, Soichi
Takaya, Hiroaki
Inoue, Takashi
Noguchi, Ryuichi
Fujimoto, Yuki
Enomoto, Masahide
Nishimura, Norihisa
Kitagawa, Koh
Kaji, Kosuke
Kawaratani, Hideto
Akahane, Takemi
Mitoro, Akira
Yoshiji, Hitoshi
Macrophage Activation Markers Predict Liver-Related Complications in Primary Biliary Cholangitis
title Macrophage Activation Markers Predict Liver-Related Complications in Primary Biliary Cholangitis
title_full Macrophage Activation Markers Predict Liver-Related Complications in Primary Biliary Cholangitis
title_fullStr Macrophage Activation Markers Predict Liver-Related Complications in Primary Biliary Cholangitis
title_full_unstemmed Macrophage Activation Markers Predict Liver-Related Complications in Primary Biliary Cholangitis
title_short Macrophage Activation Markers Predict Liver-Related Complications in Primary Biliary Cholangitis
title_sort macrophage activation markers predict liver-related complications in primary biliary cholangitis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456095/
https://www.ncbi.nlm.nih.gov/pubmed/36077228
http://dx.doi.org/10.3390/ijms23179814
work_keys_str_mv AT fujinagayukihisa macrophageactivationmarkerspredictliverrelatedcomplicationsinprimarybiliarycholangitis
AT namisakitadashi macrophageactivationmarkerspredictliverrelatedcomplicationsinprimarybiliarycholangitis
AT tsujiyuki macrophageactivationmarkerspredictliverrelatedcomplicationsinprimarybiliarycholangitis
AT suzukijunya macrophageactivationmarkerspredictliverrelatedcomplicationsinprimarybiliarycholangitis
AT muratakoji macrophageactivationmarkerspredictliverrelatedcomplicationsinprimarybiliarycholangitis
AT takedasoichi macrophageactivationmarkerspredictliverrelatedcomplicationsinprimarybiliarycholangitis
AT takayahiroaki macrophageactivationmarkerspredictliverrelatedcomplicationsinprimarybiliarycholangitis
AT inouetakashi macrophageactivationmarkerspredictliverrelatedcomplicationsinprimarybiliarycholangitis
AT noguchiryuichi macrophageactivationmarkerspredictliverrelatedcomplicationsinprimarybiliarycholangitis
AT fujimotoyuki macrophageactivationmarkerspredictliverrelatedcomplicationsinprimarybiliarycholangitis
AT enomotomasahide macrophageactivationmarkerspredictliverrelatedcomplicationsinprimarybiliarycholangitis
AT nishimuranorihisa macrophageactivationmarkerspredictliverrelatedcomplicationsinprimarybiliarycholangitis
AT kitagawakoh macrophageactivationmarkerspredictliverrelatedcomplicationsinprimarybiliarycholangitis
AT kajikosuke macrophageactivationmarkerspredictliverrelatedcomplicationsinprimarybiliarycholangitis
AT kawaratanihideto macrophageactivationmarkerspredictliverrelatedcomplicationsinprimarybiliarycholangitis
AT akahanetakemi macrophageactivationmarkerspredictliverrelatedcomplicationsinprimarybiliarycholangitis
AT mitoroakira macrophageactivationmarkerspredictliverrelatedcomplicationsinprimarybiliarycholangitis
AT yoshijihitoshi macrophageactivationmarkerspredictliverrelatedcomplicationsinprimarybiliarycholangitis